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The development of novel and efficient antiplatelet agents that have few adverse effects and methods that improve antiplatelet 
resistance has long been the focus of international research on the prevention and treatment of cardiovascular and cerebrovas-
cular diseases. Recent advances in platelet proteomics have provided a technology platform for high-quality research of plate-
let pathophysiology and the development of new antiplatelet drugs. The study of blood stasis syndrome (BSS) and activated 
blood circulation of traditional Chinese medicine (TCM) is one of the most active fields where the integration of TCM and 
western medicine in China has been successful. Activated blood circulation herbs (ABC herbs) of Chinese medicine are often 
used in the treatment of BSS. Most ABC herbs have antiplatelet and anti-atherosclerosis activity, but knowledge about their 
targets is lacking. Coronary heart disease (CHD), BSS, and platelet activation are closely related. By screening and identifying 
activated platelet proteins that are differentially expressed in BSS of CHD, platelet proteomics has helped researchers interpret 
the antiplatelet mechanism of action of ABC herbs and provided many potential biomarkers for BSS that could be used to evalu-
ate the clinical curative effect of new antiplatelet drugs. In this article the progress of platelet proteomics and its advanced appli-
cation for research of BSS and ABC herbs of Chinese medicine are reviewed. 
platelet proteomics, blood stasis syndrome, activated blood circulation, coronary heart disease, Chinese medicine, acti-
vated blood circulation herbs 
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Platelets are micro bioactive matter, which originates from 
the cytoplasm of bone marrow megakaryocyte. They play a 
pivotal role in many pathophysiologic processes, including 
hemostasis, inflammation, thrombogenesis, and organ-graft 
rejection. Acute thrombus formation, secondary to rupture 
of vulnerable atherosclerotic plaque triggered by platelet 
activation and inflammation, is the principal pathophysio-
logical basis of acute vascular events. Antiplatelet drugs 
such as aspirin and clopidogrel are used in the prevention 
and treatment of cardiovascular and cerebrovascular diseas-
es [1]. However, prolonged treatment with dual or triple 
antiplatelet drugs revealed a diversity of platelet reactions, 
including either poor or hyper responses. In poor responses, 
recurrent cardiovascular events still occurred in individuals 
who were taking enough antiplatelet drugs in a timely man-
ner, which led to antiplatelet resistance [2,3]. The hyper 
response resulted in increased risk of bleeding in the diges-
tive and nervous systems, which limits the clinical admin-
istration of antiplatelet drugs. These findings suggested that 
other pathways capable of stimulating platelet activation 
may exist. The discovery of novel classes of antiplatelet 
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agents that possess high efficiency with few adverse effects 
and the development of methods to improve antiplatelet 
resistance have long been research focuses for the prevention 
and treatment of cardiovascular and cerebrovascular diseases. 
1  Platelet proteomics 
Proteomics focuses on the composition and changing pro-
files of all the proteins in a cell or tissue, which provides 
new ideas and strategies for disclosing the molecular mech- 
anisms behind serious diseases and identifying targets for 
intervention drugs. Platelets are anuclear cells, which con-
tain intracellular granules, such as alpha granules, dense 
body, and lysosomes. Platelets are ideal targets for prote-
omics because of their functions in protein synthesis and 
modification followed by the transcription of megakaryo-
cyte. Proteomics was used to identify differential expression 
patterns between resting and activated platelets proteins 
under resting or activating condition, and signal transduc-
tion pathways related to platelet metabolism were also iden-
tified [4]. Thus, platelet functional changes in normal and 
pathological states were identified, which enriched the un-
derstanding of the biological function of platelets. High-     
throughput proteomics has made possible the screening of 
new antiplatelet agents. Two-dimensional fluorescence dif-
ference gel electrophoresis (2-D DIGE) is an ideal tech-
nique for the analysis of differentially expressed proteins. 
2-D DIGE has wonderful reproducibility, which helps avoid 
the low reproducibility and serious systematic variations 
that often occur in traditional two-dimensional gel electro-
phoresis. Matrix-assisted laser desorption/ionization time-     
of-flight/time-of-flight (MALDI-TOF-TOF) tandem mass 
spectrometry accompanied by 2-D DIGE, has high sensitiv-
ity and specificity. Platelet proteomics has been applied 
successfully to early diagnosis and new drug research, and 
to understand the development of serious diseases, such as 
hematological diseases and coronary heart disease. The re-
search model usually contains three steps: screening, identi-
fication (qualitative and quantitative), and functional analy-
sis [5–7].  
In a 2012 paper, Burkhart et al. [8] reported the first 
comprehensive and quantitative human platelet proteome by 
quantitative mass spectrometry. They identified more than 
2500 phosphorylation sites, almost 4000 unique proteins, 
and estimated the copy numbers per platelet for 3700 of 
them. In addition, 1900 proteins were quantified between 
four different donors (intersubject variation) and 1500 pro-
teins between three different blood samples from the same 
volunteer (intrasubject variation). The results demonstrated 
that, in both cases, 85% of the platelet proteome showed no 
variation. This study provided a basis for subsequent func-
tional analyses of screened platelet proteins. 
2  Platelet proteomics and blood stasis syn-
drome of Chinese medicine 
Proteomics looks at the characteristics of protein activity on 
the whole, which is similar to the holistic view in traditional 
Chinese medicine (TCM) theory. In recent years, clinical 
medicine has moved from a fragmented approach to a more 
holistic integrative model [9]. In the real medical environ-
ment, western medicine and TCM have merged to become 
the Chinese integrative medicine, a unique medical system 
in China. A research model that combines “disease”, diag-
nosed by western medicine, and “syndrome”, recognized by 
TCM theory, is one of the directions in which Chinese inte-
grative medicine will develop in the future [10]. Functional 
proteomics could be used to detect the differential expres-
sion patterns of proteins in typical syndromes defined by 
TCM theory. All the proteins associated with a syndrome 
could be analyzed and characterized to describe the TCM 
syndrome at the overall protein expression level and to pro-
vide scientific evidence for the syndrome [11]. 
Blood stasis syndrome (BSS) is defined by TCM theory 
and has the status of platelet activation. A previous study 
demonstrated that coronary heart disease (CHD), BSS, and 
platelet activation were closely related [12]. Using the 
well-established diagnostic criteria of BSS, we set up a di-
agnostic criteria of BSS of CHD [13]. Platelets play an im-
portant role in the formation of coronary artery thrombosis, 
and activated platelets not only participate in the formation 
of blood clots, but also release a variety of vascular active 
substances, cytokines and growth factors that are involved 
in the formation and development of atherosclerosis. BSS 
has a close relationship with many pathological physiology 
changes, including microcirculation disturbance, high blood 
viscous state, and platelet activation and adhesion. BSS is 
the most common TCM syndrome type of CHD, and a pre-
vious study reported that BSS of CHD had the status of 
platelet activation [14]. 
Taking the BSS of CHD and activated blood circulation 
(ABC) herbs as the starting point, we applied platelet pro-
teomics to study BSS and the effects of ABC herbs. In a 
previous study [15], 45 differentially expressed platelet 
proteins between BSS of CHD and non-BSS of CHD (Fig-
ure 1) were identified by platelet proteomics and screened 
based on a three-dimensional diagram, isoelectric point, 
molecular weight, and degree of information matching to 
the real position in the gel. As a result, 23 platelet protein 
points were identified. Mass spectrum successfully identi-
fied 14 different platelet proteins (Table 1), and after re-
moving four redundancies, 10 differentially expressed 
platelet proteins with reliable supporting data remained. 
Most of these proteins were annotated as platelet cytoskele-
ton proteins or platelet membrane proteins. In addition to 
causing changes in the membrane proteins, platelet activa-
tion, which depends on the regulation of platelet cytoskelet- 
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Figure 1  Differentially expressed platelet proteins between BSS and non-BSS of CHD groups (reproduced from Figure 31 of reference [15] with the au-
thor’s authorization). 
al protein, can also trigger a series of morphological chang-
es from inviscid discotic circulating platelets into a paste- 
like protruding platelet jelly. For clinical verification, we 
chose gelsolin because a literature search revealed that it 
has a clear function. Our results confirmed that the platelet 
gelsolin level in BBS patients of CHD increased signifi-
cantly compared with that in non-BSS patients of CHD and 
healthy subjects [16], revealing that gelsolin had a close 
relationship with BSS of CHD and indicating that platelet 
cytoskeletal protein may play an important role in the de-
velopment of BSS of CHD. In addition, we observed a clin-
ical correlation between the platelet gelsolin level of differ-
ent types of CHD (stable CHD and acute coronary syn-
drome), showing that the platelet gelsolin level had a posi-
tive relation with acute coronary syndrome [17]. 
The role of gelsolin in cardiovascular diseases is attract-
ing more and more attention worldwide and several studies 
have indicated that gelsolin plays an important role in the 
development of CHD, arrhythmia, and ventricular remodel-
ing after acute myocardial infarction [18,19]. Gelsolin is an 
important cytoskeletal protein and a high concentration of 
calcium activates the secretion of gelsolin. After infarction, 
myocardial F-actin is released into the circulation, which 
can be fatal for endothelial cells and micrangium. An extra-
cellular actin scavenger system is therefore likely to exist 
[20], and plasma gelsolin and Gc-globulin, another extra-
cellular actin-binding protein, have been regarded as poten-
tially important components of a system that would be ca-
pable of removing F-actin from the circulation and inhibit-
ing F-actin elongation. Platelet gelsolin and the platelet ac-
tivation level of BSS of CHD have a high positive correla-
tion. During platelet activation of BSS of CHD, the compo-
sition of cytoskeletal protein varies, including the platelet 
gelsolin and F-actin concentrations. We speculate that there 
might be an abnormal increase in platelet gelsolin as a result 
of reactive restructuring of platelet cytoskeleton because of 
the depletion of plasma gelsolin or increased calcium influx 
in platelets during the development of BSS of CHD. This 
process could promote the platelet activation and transfor-
mation involved in the progress of BSS of CHD. Therefore, 
platelet gelsolin is a new potential biomarker of BSS in 
CHD [16]. 
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Table 1  Identified platelet proteins differentially expressed between BSS and non-BSS of CHD groupsa) 












Gene_Symbol=ITGA2B Isoform 2 of 
Integrin alpha-IIb 
109518.5 5.17 751 100 651 100 3 
IPI00877792 Gene_Symbol=FGG 50 kD protein 50290.4 5.71 141 100 62 99.929 32 
IPI00739539 Gene_Symbol=A26C1B ANKRD26-like 121292.7 5.86 170 100 143 100 36 




41709.7 5.29 445 100 330 100 38 
IPI00021439 
Tax_Id=9606 Gene_Symbol=ACTB 
Actin, cytoplasmic 1 












41709.7 5.29 588 100 478 100 42 
IPI00894365 
Gene_Symbol=ACTB cDNA FLJ52842, 
highly similar to Actin, cytoplasmic 1 
39200.5 5.4 442 100 326 100 43 
IPI00794523 
Tax_Id=9606 Gene_Symbol=ACTG1 
cDNA FLJ43573 fis, clone 
RECTM2001691, highly similar to 
Actin, cytop 
28193 5.2 236 100 189 100 66 
IPI00298497 
Gene_Symbol=FGB Fibrinogen beta 
chain 
55892.3 8.54 80 99.924 59 99.867 63 
IPI00009865 
Gene_Symbol=KRT10 Keratin, type I 
cytoskeletal 10 
59474.9 5.13 141 100 56 99.903 23 
IPI00796316 
Gene_Symbol=GSN cDNA FLJ53327, 
highly similar to Gelsolin 
77741.1 5.47 83 99.958 40 95.153 62 
a) Reproduced from Table 13 of reference [15] with the author’s authorization. Accession No. in italics and underlined indicate the redundant proteins. 
Spot number indicates the number of differentially expressed platelet proteins in protein glue figure. 
 
 
3  Platelet proteomics and research of activated 
blood circulation herbs of Chinese medicine 
ABC herbs and formulas are the main drugs that are used in 
the clinical treatment of BSS in TCM theory. During the 
past 50 years, much theoretical and experimental progress 
has been made in the fields of TCM. As a result, the regula-
tion and principles of treatments that use ABC herbs and 
formulas have been clarified and such treatments are now 
accepted by the medical community all over the world [21]. 
Chinese and western medicines agree that stabling plaque 
and activating blood circulation can help prevent athero-
sclerosis and vulnerable plaque. In this context, the applica-
tion of ABC herbs and formulas has valuable significance in 
reducing the risk of cardiovascular event [22]. Studies have 
shown that ABC herbs such as Danshen (Salvia miltiorrhi-
za), Danpi (Paeonia suffruticosa Andr.), Danggui (Angelica 
sinensis), Chishao (Paeonia veitchii), Puhuang (Typha an-
gustifolia pollen), Chuanxiong (Ligusticum sinense) and 
Sanqi (Panax notoginseng), and formulas such as Xue-Fu- 
Zhu-Yu decoction, compositus Guan-Xin No.2, and Tao- 
Hong-Si-Wu decoction have antiplatelet and anti-inflam- 
matory action. The effective constituents of ABC herbs in-
clude flavonoids (puerarin and carthamin yellow), alkaloids 
(ligustrazine and all the Chuanxiong alkaloids, terpenes 
(tanshinone and Panax notoginseng saponins), organic acids 
(tanshinol and salvianolic acid). Most of the previous re-
search focused on pharmacology observations such as 
platelet aggregation rate and platelet receptors, and rarely 
on protein expression after platelet activation [23]. There-
fore, studies on the targets and signaling pathways that are 
involved in reducing the risk of cardiovascular disease are 
needed. Platelet proteomics can help identify more potential 
targets, which may elucidate the mechanisms of action of 
the ABC herbs and formulas based on the TCM theory of 
“correspondence of formula to syndrome” [24]. 
3.1  Chishao and Chuanxiong 
Chishao and Chuanxiong are classical ABC herbs that have 
been used for thousands of years in the prevention and 
treatment of cardiovascular diseases in China. Studies indi-
cated that these two herbs have ideal antiplatelet aggrega-
tion and anti-thrombosis action. The Xiongshao capsule 
(XSC) is a patented drug developed from Xue-Fu-Zhu-Yu 
decoction. It is a classic formula that has been used for 
hundreds of years in China to activate blood circulation. 
The effective components of XSC are Chuanxiong rhizome 
and red peony (Paeonia lactiflora) root. Experimental studies 
have shown that XSC dilate coronary arteries, thereby im-
proving myocardial ischemia and hypoxia, promoting an-
tiplatelet aggregation, inhibiting smooth muscle prolifera-
tion, inhibiting lipid peroxidation, and promoting angiogen-
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esis [25–27]. Clinical studies have shown that XSC can ef-
fectively prevent restenosis after percutaneous coronary 
intervention [28,29]. Platelet plays vital roles in the devel-
opment of atherosclerosis, rupture of vulnerable plaque, and 
formation of thrombogenesis. By elucidating the antiplatelet 
mechanism and targets of XSC, new ideas for antiplatelet 
therapy may be revealed. 
As was mentioned above, it was suggested that excessive 
F-actin at the platelet activation stage of BSS of CHD might 
deplete plasma gelsolin and directly stimulate platelet to 
secrete abnormal amounts of gelsolin. If this is the case, 
then platelet gelsolin may be the therapeutic target of the 
antiplatelet activation effect of ABC herbs and formulas. To 
further investigate these proposals, we build an experi-
mental in vitro model system of platelet activation and an in 
vivo myocardial infarction rat model. We found that F-actin 
can induce platelet aggregation and activation in vitro, and a 
high concentration of F-actin can increase the platelet gel-
solin level of activated platelet, which is similar to the effect 
of arachidonic acid reported previously [30]. Paeoniflorin 
and ligustrazine phosphate can inhibit platelet aggregation 
and activation in vitro and can also reduce the platelet gel-
solin level of activated platelet. Aspirin had no such effect 
in vitro. The active ingredients of Chuanxiong rhizome and 
red peony root (chuangxiongol and paeoniflorin) can reduce 
the platelet gelsolin level, enhance the activity of the extra-
cellular actin scavenger system, and inhibit platelet activa-
tion, which is similar to the effect of calcium antagonist 
[31]. The above series of studies confirmed the idea that 
platelet gelsolin may be an effective target for ABC herbs 
and formulas. 
3.2  Sanqi and Danshen 
Sanqi is a medicinal drug with a history of more than 500 
years (according to the Ben Cao Gang Mu (Compendium of 
Materia Medica)), which contains saponin, flavones, and 
protein and non-protein amino acids. Saponin is found in 
higher proportions than the other components, and is the 
component that activates blood circulation. To identify the 
possible target proteins of Sanqi in platelets, comparative 
proteomics using two-dimensional gel electrophoresis was 
performed and the proteins that showed altered expression 
levels after Sanqi treatment were identified by MALDI-      
TOF tandem mass spectrometry. It was reported that Sanqi 
treatment regulated the levels of 12 proteins that play im-
portant roles in platelet activation, oxidative stress, and cy-
toskeleton. In the Sanqi-treated platelets compared with 
non-treated platelets, there were increased levels of growth 
factor receptor-bound protein 2 (Grb2), thrombospondin 1, 
and tubulin alpha 6, and decreased levels of thioredoxin, 
Cu-Zn superoxide dismutase, DJ-1 protein, peroxiredoxin 3, 
thioredoxin-like protein 2, ribonuclease inhibitor, potassium 
channel subfamily V member 2, myosin regulatory light 
chain 9, and laminin receptor [32]. 
Danshen was first recorded in Sheng Nong’s Herbal 
Classic work as having the effect of activating blood circu-
lation and it is still widely used in TCM for the treatment of 
cardiovascular disorders. The chemical components of 
Danshen are fat-soluble diterpene quinines (tanshinone I, 
IIA, IIB) and water-soluble phenolic acids (salvianolic acid 
B and tanshinol). Salvianolic acid B has been shown to be 
an active component. Differential proteomic analysis by 
two-dimensional electrophoresis was conducted to check 
the protein expression profiles of rat platelets with and 
without salvianolic acid B treatment. Proteins with altered 
expression levels after salvianolic acid B exposure were 
identified by MALDI-TOF tandem mass spectrometry. Sal-
vianolic acid B treatment was found to regulate the expres-
sion of 20 proteins such as platelet aggregation and blood 
coagulation related proteins (e.g., the platelet-activating 
factors acetylhydrolase Ib-β and prothrombinase FGL-2), 
cellular transmembrane signal transduction related proteins 
(e.g., potassium voltage-gated channel, 14-3-3ε  and copine 
J), material energy metabolism related proteins (e.g., al-
dolase A), cytoskeletal protein (coronins and tropomyosin), 
and other proteins such as heat shock-related 70, peroxire-
doxin-2, and zinc finger proteins [33]. 
4  Conclusion and perspectives 
Chinese integrative medicine is an important part of com-
plementary and alternative medicine in the world. Its out-
standing achievements include arsenic trioxide for leukemia, 
artemisinin and its derivative for malaria, and activated 
blood circulation herbs for cardiovascular diseases, all of 
which have been approved worldwide in the medical field 
[34]. The future development of TCM needs the inputs that 
modern science can provide [35]. An exploration of the 
mechanisms of action of the existing herbs and formulas is 
one of the major directions that Chinese integrative medi-
cine can take. 
ZHENG is a syndrome or pattern that is at the core of 
TCM theory. The essence of ZHENG is not only the de-
mand for the development of TCM, but is also the inevita-
ble choice of the modernization of TCM. Platelet plays an 
important role in the formation of atherosclerotic throm-
bosis, which is the common pathology that underlies many 
cardiovascular and cerebrovascular diseases. The emer-
gence and development of platelet proteomics has provided 
a technological platform that can be used to explore the es-
sence of ZHENG based on the “combination of disease and 
syndrome”. Platelet proteomics could be applied to identify 
potential biomarkers of ZHENG by comparing platelet pro-
teomes from patients with different ZHENG syndromes. 
Guided by the TCM theory of “correspondence of formula 
to syndrome” or “correlation between formula and syn-
drome” [36], targets could be identified by analyzing the 
expression levels of platelet proteins before and after inter-
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vention with a therapy or formula, the mechanism of action 
of formulas could be obtained, and the clinical effects of 
new antiplatelet drugs could be screened and evaluated. 
Currently, platelet proteomics tends to stop at the screening 
and identification stage, and only rarely is extended to the 
functional analysis of the differentially expressed platelet 
proteins. The difficulty of identifying low abundance plate-
let proteins and methods to analyze the massive amounts of 
data that are obtained, are issues that need to be addressed 
in future platelet proteomics research. The abundant re-
search achievements that have already been obtained using 
platelet proteomic techniques and its continued application 
to the study of BSS and ABC herbs, will surely reveal many 
more amazing new results and findings, which in turn will 
help decrease the morbidity and mortality caused by cardio- 
vascular and cerebrovascular diseases. 
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